All In Biotech

Drug Trial Radar · NCT01039506

An Observational Study of CPT-11 Based Regimens and UGT1A1 Genotypes in Metastatic Colorectal Cancer (mCRC)

A Prospective Observational Study of the Efficacy and Safety of CPT-11 Based Regimens for UGT1A1 Genotype Guided Patients With Metastatic Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: May 29, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

1,376

Actual

Start

Oct 15, 2009

Primary completion

Apr 28, 2016

Study completion Jul 1, 2016

Sponsor

Lead sponsor
Daiichi Sankyo Co., Ltd.Daiichi Sankyo (DSNKY)
Sponsor type
Industry
First posted
Dec 25, 2009

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to examine the correlation between UGT1A1 genotypes and the efficacy of CPT-11 based regimens (FOLFIRI, CPT-11+S-1, CPT-11) for patients with metastatic colorectal cancer.

Conditions

  • Metastatic Colorectal Cancer

Interventions

  • CPT-11 based regimensDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survivalTime frame: Within 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Clinical Oncology, National Defense Medical College Hospital

    Tokorozawa-shi, Saitama, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.